News Solomon quits as Akari CEO following credit card probe Biotech veteran quits after less than a year in charge
News Akari soars ahead of read-out for Soliris rival Investors are anticipating good news from a potential rival to Alexion’s rare disease blockbuster Soliris, with shares in the company behind it soaring.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
